MARKET

SYRE

SYRE

Spyre Therapeutics
NASDAQ
101.85
-2.24
-2.15%
After Hours: 102.50 +0.65 +0.64% 16:57 08/13 EDT
OPEN
101.00
PREV CLOSE
104.09
HIGH
103.84
LOW
100.90
VOLUME
525.39K
TURNOVER
--
52 WEEK HIGH
108.14
52 WEEK LOW
14.51
MARKET CAP
8.98B
P/E (TTM)
-43.8593
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)
TipRanks · 7h ago
Dual TL1A and IL-17A/F Trial in Hidradenitis Suppurativa Could Be A Game Changer For Spyre Therapeutics (SYRE)
Simply Wall St · 1d ago
Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Spyre Therapeutics (SYRE) and IDEAYA Biosciences (IDYA)
TipRanks · 2d ago
Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Spyre Therapeutics (SYRE) and Innate Pharma (IPHA)
TipRanks · 2d ago
Spyre Therapeutics Price Target Raised to $132.00/Share From $112.00 by BTIG
Dow Jones · 2d ago
Spyre Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 2d ago
More
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).

Webull offers Spyre Therapeutics Inc stock information, including NASDAQ: SYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRE stock methods without spending real money on the virtual paper trading platform.